Dietary Supplement for Myopia Control
Key facts
- Who runs it
- The Hong Kong Polytechnic University
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 156 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Oral dietary supplement provided in a capsule format (3 active capsules/ per day)
- Oral dietary supplement provided in a capsule format (1 active capsule and 2 placebo capsules/per day)
- Placebo control (3 placebo capsules/per day)
- Record updated
- 24 July 2026
Who can take part
- Age
- 8 years to 13 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age 8-13 years
- Cycloplegic spherical equivalent refraction (SER) of -0.50 D to -5.00 D with astigmatism of 2.5 D or less and best-corrected visual acuity (BCVA) of 0.0 logarithm or more in either eye
- Anisometropia of 1.50 D or less
- Intraocular pressure of 10 mmHg to 21 mmHg in both eyes
- Willing to give written consent to participate in the study and accept random allocation in grouping
Who cannot take part
- Receiving previous myopia control treatment including but not limited to atropine therapy and orthokeratology in the past 3 months
- Ocular abnormalities leading to visual impairment
- Severe physiological and psychological diseases affecting follow-up
- Known history of allergy to any of the components of the dietary supplement or placebo, or history of an allergic reaction that required emergency treatment
- Use of any other dietary supplements containing DHA/EPA, Lutein, or Astaxanthin in the past 3 months
- Children who had other contraindications identified by the investigators that made them unsuitable for participation
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 8 and 13 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this clinical trial is to investigate the changes in choroidal thickness and vasculature in myopic children following oral supplementation.
The 3 groups in the trial
- High concentration groupTreatment being tested
3 active capsules/ per day
Treatment: Oral dietary supplement provided in a capsule format (3 active capsules/ per day)
- Low-concentration groupTreatment being tested
1 active capsule and 2 placebo capsules/per day
Treatment: Oral dietary supplement provided in a capsule format (1 active capsule and 2 placebo capsules/per day)
- Control groupPlacebo, for comparison
3 placebo capsules/per day
Treatment: Placebo control (3 placebo capsules/per day)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Dietary Supplements on Choroidal Thickness and Vasculature in Myopic Children: A Randomized, Double-Blind, Placebo-Controlled Trial
- Criteria questions
- Built from NCT07406906, who can take part
- Record updated
- 24 July 2026